Exelixis Acquires GamaMabs' Oncology Antibody Program to Expand its Biotherapeutics Portfolio
Shots:
- Exelixis to acquire GamaMabs' AMHR2 Ab technology for $5M and additionally payment upon achieving certain milestones. Following the closing of the transaction- Exelixis will control GamaMabs’ AMHR2 franchise technology including all assets related to murlentamab (GM-102)
- The preclinical data support the potential of AMHR2 for novel oncology therapies and demonstrated the safety of an anti-AMHR2 mAbs in human clinical trials
- Exelixis expands its biotherapeutics portfolio by integrating its ADC capabilities to GamaMabs’ Abs against AMHR2 and helps to provide rapid and effective development of cancer therapies
Ref: BUSINESS WIRE | Image: Exelixis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com